- Home
- KLRS vs MREO Comparison
KLRS vs MREO Comparison
Compare KLRS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | MREO |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | 39 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KLRS | MREO |
|---|---|---|
| Price | $5.32 | $0.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $20.67 | $1.50 |
| AVG Volume (30 Days) | 52.1K | ★ 1.3M |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $6,756.00 |
| Revenue Next Year | N/A | $38.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $0.20 |
| 52 Week High | $11.88 | $2.94 |
Technical Indicators
Market Signals| Indicator | KLRS | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 22.41 | 31.69 |
| Support Level | $5.10 | $0.20 |
| Resistance Level | $5.38 | $0.42 |
| Average True Range (ATR) | 0.71 | 0.03 |
| MACD | -0.32 | 0.00 |
| Stochastic Oscillator | 0.42 | 1.69 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).